New drug with pembrolizumab for advanced melanoma
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug (EIK1001) combined with the standard immunotherapy pembrolizumab (Keytruda) for people with advanced melanoma that cannot be removed by surgery or has spread. The goal is to see if adding EIK1001 is more effective than placebo plus pembrolizumab.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have stage 3 or 4 melanoma that cannot be surgically removed or has spread, and you are eligible for pembrolizumab treatment.
- You have not had prior systemic therapy (medication that travels through the body) for advanced melanoma, though prior adjuvant or neoadjuvant therapy for earlier stages is allowed if at least 6 months have passed since the last dose and the disease has progressed.
- Your tumors can be measured on a CT scan or MRI, and your overall health status (ECOG) is 0 or 1 (meaning you are fully active or only limited in strenuous activity).
- Your major organs (bone marrow, liver, kidneys) are functioning well enough based on standard blood tests.
- You do not have active brain metastases that are growing or require high-dose steroids, active autoimmune disease requiring systemic treatment in the last 2 years, or a history of lung inflammation needing steroids.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immunotherapy drug (IMC-F106C) combined with standard treatments against the usual nivolumab-based therapy for people with advanced melanoma who have not been treated before. It's for people who carry a specific immune system marker (HLA-A*02:01) and are in fairly good health.
This trial tests a new drug called OPM-101 combined with an immunotherapy (anti-PD-1) for people with advanced melanoma that has stopped responding to anti-PD-1 treatment. The goal is to see if the combination can overcome resistance and shrink tumors.
This trial tests a new drug called LM103 for people with advanced melanoma who have already tried several standard treatments, including immunotherapy. The goal is to see if LM103 can help shrink tumors when other treatments have stopped working.
This trial is testing a combination of two immunotherapy drugs (anti-LAG-3 and anti-PD-1 antibodies) to see if they work better than standard treatment for people with advanced melanoma that hasn't been treated before. It may be an option if you have not yet received any systemic therapy for your melanoma.
This early-stage trial tests a new investigational drug (ADG126) combined with pembrolizumab in people with advanced or metastatic solid tumors. It aims to find a safe dose and see whether the combination can shrink tumors.
This study tests an experimental drug called EIK1005, either alone or combined with another drug (pembrolizumab), for people with advanced solid tumors, especially those with MSI-H or dMMR cancers (tumors that have trouble repairing their DNA). The goal is to see if it can shrink tumors or slow cancer growth.
Hear when a new Advanced Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.